Abstract
Background: Compound Danshen dripping pills (CDDP), a traditional Chinese medicine, has had
an extensive application in the treatment of angina pectoris (AP) in China. However, research on the bioactive
ingredients and underlying mechanisms of CDDP in AP remains unclear.
Objective: In the present study, we explored the major chemical components and potential molecular mechanisms
linked to the anti-angina effects of CDDP through the application of network pharmacology and molecular
docking.
Methods: The potential targets of active ingredients in CDDP were sourced from the Traditional Chinese
Medicine Systems Pharmacology Database (TCMSP) and the Swiss Target Prediction Database (STPD). Additionally,
targets related to angina pectoris (AP) were retrieved from various databases, including Gene Cards,
DisGeNET, Dis Genet, the Drug Bank database (DBD), and the Therapeutic Target Database (TDD). Protein-
protein interaction networks were also established, and core targets were identified based on their topological
significance. GO enrichment analysis and KEGG pathway analysis were conducted using the R software.
Interactions between active ingredients and potential targets selected through the above process were investigated
through molecular docking.
Results: Seventy-six active ingredients were selected with the following criteria: OB ≥ 30%, DL ≥ 0.18. 383
targets of CDDP and 1488 targets on AP were gathered, respectively. Afterwards, 194 common targets of CDDP
and anti-AP targets were defined, of which 12 were core targets. GO enrichment analysis indicated that
CDDP acted on AP by response to lipopolysaccharide, regulating the reactive oxygen species and metal ion
metabolism, and epithelial cell proliferation. In addition, KEGG enrichment analysis indicated that the signaling
pathways were notably enriched in lipid and atherosclerosis, fluid shear stress and atherosclerosis, IL-17
signaling pathway, EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, and TNF signaling
pathway. Moreover, the molecular docking manifested excellent binding capacity between the active ingredients
and targets on AP.
Conclusion: This study comprehensively illustrated the bioactive, potential targets, and molecular mechanisms
of CDDP against AP, offering fresh perspectives into the molecular mechanisms of CDDP in preventing
and treating AP.
Keywords:
Compound Danshen dripping pills, angina pectoris, network pharmacology, molecular docking, TCMSP, protein-protein interaction.
[4]
Gillen C, Goyal A. Stable angina. StatPearls. Treasure Island (FL): StatPearls Publishing 2022.
[8]
Conti CR. Treatment of ischaemic heart disease. Role of drugs, surgery and angioplasty in unstable angina patients. Eur Heart J 1997; 18: B11-5.
[14]
Li M, Ding YT, Miao X, et al. Difference between ancient and modern syndrome-treatment in Chest Bi and causes analysis. J Tradit Chin Med 2018; 59: 546-9.
[15]
Li L, Liu JX. Current status of integrating syndrome and objective research in coronary heart disease with blood stasis syndrome. J Herb Med 2008; 2008: 396-397+400.
[17]
Li Q. Research progress and clinical application of Compound Danshen dripping pills. Chin J Trad Chin Med Phar 2018; 33(7): 2989-91.
[19]
Xiao Y, Liu YJ. Meta-analysis of CSDP for coronary heart disease angina. Chin J Drug Eval 2013; 30: 32-6.
[20]
Xue JZ, Chen Y, Ma Z, Si X, Feng WY. Meta analysis of efficacy comparison of Compound Danshen dropping pills and isosorbide mononitrate in treatment for angina pectoris of coronary heart disease. Chin Med J 2013; 2013: 35.
[21]
Li J, Wang Q. Research progress on the pharmacological effects of Compound Danshen dripping pills in the treatment of coronary heart disease. Shanxi J Trad Chin Med 2001; 2001: 56-7.
[22]
Guo J, Zhang L, Zeng Z, et al. Effects of Compound Danshen root dropping pill on hemorheology in high-fat diet induced hyperlipidemia in dogs. Clin Hemorheol Microcirc 2005; 32(1): 19-30.
[26]
Wang YP. Research on the mechanism of Compound Danshen dripping pills in treating coronary heart disease. Clin J Anhui Trad Chin Med 2001; 2001: 13.
[29]
Zhang H, Cheng Y. Solid-phase extraction and liquid chromatography-electrospray mass spectrometric analysis of saponins in a Chinese patent medicine of formulated Salvia miltiorrhizae and Panax notoginseng. J Pharm Biomed Anal 2006; 40: 429-32.
[30]
Phase II multi-center study of T89 to treat chronic stable angina (T89 phase 2). Patent NCT00797953, 2008.
[31]
Phase III trial of dantonic® (T89) capsule to prevent and treat stable angina. Patent NCT01659580, 2017.
[32]
Sun H, Guo ZX, Li LY, et al. Case study of compound traditional Chinese medicine globalization. Modern Trad Chin Med Materia Medica-World Sci Technol 2017; 19: 914-23.
[52]
LI Q. Research progress and clinical application of Compound Danshen dripping pills. Chin J Chin Mater Medica 2018; 33: 2989-91.
[53]
Hao CW, Li ZX, Zhang MH, Han B. Research progress of Salvia miltiorrhiza and its compatible preparations in treatment of coronary heart disease. Chin Tradit Herbal Drugs 2021; 52: 4096-106.
[54]
Yang Y, Wang XL, Bi YF, et al. Meta-analysis and GRADE assessment of Compound Danshen dripping pills combined with conventional western medicine treatment for unstable angina. J Tradit Chin Med 2019; 60: 1815-26.
[55]
Ting-Ting Q. Meta analysis on efficacy of Compound Danshen dropping pills in treating angina based on syndrome differentiation. Chin Tradit Herbal Drugs 2020; 51: 6310-23.
Download PDF Flyer